Indications for Use

The oncoReveal™ CDx is a qualitative next generation sequencing based in vitro diagnostic test that uses amplicon-based target enrichment technology for detection of single nucleotide variants (SNVs), insertions and deletions in 22 genes using DNA isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissue specimens and using the Illumina MiSeqDx. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling.

Additionally, oncoReveal™ CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for previously diagnosed  cancer patients with solid malignant neoplasms. Genomic findings other than those listed in Table 1 are not prescriptive or conclusive for labeled use of any specific therapeutic product.

Table 1: Approved Companion Diagnostic and Tumor-Profiling Indications

Table 1. Approved Companion Diagnostic and Tumor-profiling Indications

Table 2: oncoReveal™ CDx gene list*

Table 2. oncoReveal CDx gene list

oncoReveal™ CDx Technical Specifications

oncoReveal CDx Technical Specifications

Ordering Information

For more information about the oncoReveal CDx product, click here to download the oncoReveal CDx User Manual: